澳门葡京网赌游戏
澳门葡京赌博游戏是全球性的, 科学, patient-focused pharmaceutical business, committed to excellence in the research, development and commercialisation of prescription medicines.
澳门葡京赌博游戏差异化和不断增长的已获批药物组合、全球影响力和丰富的研发资源&D管道给了澳门葡京赌博游戏信心,澳门葡京赌博游戏将在近期和中期继续以比行业更快的速度增长.
澳门葡京网赌游戏(AstraZeneca)董事长米歇尔
Our vision for health is not a short-term one. While maintaining our focus on discovering new small and large molecules, we are also increasing investment behind new modalities…
Pascal Soriot, Chief Executive Officer, AstraZeneca
战略概述
Inspired by our Values and what science can do, 澳门葡京赌博游戏专注于加速提供改变生活的药物,为患者创造持久的价值, 社会, 地球和澳门葡京赌博游戏的股东.
Our ambition is to launch at least 15 new medicines by 2030. 2023年批准了3个.
2023年成就:
56
管理事件
澳门葡京赌博游戏完成了56个监管事件, either submissions or approvals for our medicines in major markets, including three first new molecular entity (NME) approvals. We also achieved 30 pipeline progression events, either NME Phase II starts or Phase III investment decisions.
2023年成就:
$45.8bn
总营收
总营收 increased by 3% (6% at CER) to $45,811 million. 总收入(不包括COVID-19药物)增长13%(按净成本计算为15%),达到454.88亿美元.
短期目标:
98% absolute reduction in Scope 1 and 2 GHG emissions by 2026 from 2015 baseline:
澳门葡京赌博游戏正在加速提供净零卫生保健和实现净零的进展. We were one of the first companies to have our net-zero targets across Scope 1, 2和3在基于科学的目标倡议的净零企业标准下得到验证.
2023年成就:
-67.6%
Reduction in Scope 1 and 2 GHG emissions since 2015.
(2022: -59.减少3%).
短期目标:
2015 - 2025年能耗降低10%,能源生产率(EP100)翻一番.
We are investing in nature to benefit planetary and societal health, while working towards sustainable resource use, 水安全, and halting and reversing biodiversity loss.
2023年成就:
-17.5%
Reduction in energy consumption since 2015.
Net cash flow from operating activities
$10.3bn •
Up 5% at actual rate of exchange to $10,345 million
(2022年:98.08亿美元)
报告每股收益
$3.84
报告每股收益增加至3美元.84
(2022: $2.12)
核心每股收益
$7.26 •
Up 9% at actual rate of exchange to $7.26
(按成本成本计算上涨15%)
(2022: $6.66)